Whilst the gender gap remains a problem in the VC world, real progress is being made. With corporate venture capital becoming increasingly important, they also play an increasingly important role in ensuring gender parity.
Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of €35m
Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease
Largest international VC-backed Series A financing round for a biotech in Italy to date and first ever venture investment in an Italian company by both AbbVie Ventures and Roche Venture Fund
Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastrointestinal diseases and progress pipeline assets
Enthera Pharmaceuticals ( Enthera ), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, today announces the final closing of its Series A financing, with a total financing of €35m.